



## Beyond the Mu Opioid System for Treating OUD (B-MOST-O)

November 21-22, 2019  
W Hotel  
Washington, DC

### MEETING AGENDA

*This meeting is focused upon examining how outcomes, measures, risk-benefit assessments, and trial designs for studies of the treatment of opioid use disorder may need to be modified or developed as the field identifies and studies novel, non-mu opioid treatment interventions.*

#### The goals of this meeting are to:

1. review current outcome measures and trial designs used for the treatment of OUD;
2. review novel, non-mu agents that are being considered as treatments for OUD;
3. consider whether existing trial designs need to be modified or new ones established in light of these non-mu agents being considered as treatments for OUD;
4. consider whether new outcome measures need to be developed in light of these non-mu agents; and,
5. examine how risk-benefit assessments should be conducted in light of these non-mu agents.

#### Thursday, November 21: Trial designs and outcome assessments

Altitude Room

9:00 – 9:15 AM Overview to the meeting, introductions, goals  
*Eric Strain; Robert Dworkin; Dennis Turk*

#### ***Current designs and outcomes for mu agents used for the treatment of OUD***

9:15 – 9:45 AM Overview to features of clinical trials designs for traditional mu agents  
*Eric Strain*

9:45 – 10:15 AM Overview to primary and secondary outcomes measures used in studies of traditional mu agents  
*Kyle Kampman*

10:15 – 10:45 AM Break

10:45 – 11:15 AM Overview to risk assessments used when studying traditional mu agents  
*Kenzie Preston*

11:15 – 11:45 AM Group discussion regarding established designs and outcome assessments minutes

11:45 AM – 12:45 PM Lunch

POV Lounge

#### **New agents and current general approaches for studying each as a therapeutic agent**



12:45 – 1:30 PM	Cannabinoid-related compounds <i>Ryan Vandrey</i>	<b>Altitude Room</b>
1:30 – 2:15 PM	Sleep agents <i>Andrew Huhn</i>	
2:15 – 2:30 PM	Break	
2:30 – 3:15 PM	Psychedelics <i>Roland Griffiths and Matthew Johnson</i>	
3:15 – 4:00 PM	Vaccines <i>Sandra Comer and Marco Pravetoni</i>	
4:00 – 4:30 PM	Group discussion; Q&A	
7:00 – 9:00 PM	Dinner	<b>Studio 2</b>

**Friday, November 22: Designs, outcomes, risks, and benefits for non-mu agents**

7:30 – 8:30 AM	Breakfast	<b>POV Lounge</b>
8:30 – 8:45 AM	Recap Day 1; Review of goals for Day 2 <i>Eric Strain; Robert Dworkin; Dennis Turk</i>	<b>Altitude Room</b>

**Needs in the field for assessing the following specific domains, when studying non-mu agents for the treatment of OUD: designs, outcomes, risks, benefits**

**Group Discussion**

8:45 – 9:30 AM	Cannabinoid-related compounds	
9:30 – 10:15 AM	Sleep agents	
10:15 – 10:30 AM	Break	
10:30 – 11:15 AM	Psychedelics	
11:15 AM – 12:00 PM	Vaccines	
12:00 – 1:00 PM	Lunch General discussion, including agents not specifically considered Consensus and next steps	